32
Participants
Start Date
July 31, 1998
Primary Completion Date
May 31, 2000
Study Completion Date
May 31, 2000
temozolomide
Patients receive oral temozolomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients are treated at escalating doses of temozolomide. The maximum tolerated dose is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity (DLT) during courses 1 or 2, with at least 2 patients experiencing DLT at the next higher dose level.
San Antonio Cancer Institute, San Antonio
Brooke Army Medical Center, Fort Sam Houston
National Cancer Institute (NCI)
NIH
Cancer Therapy and Research Center, Texas
OTHER
The University of Texas Health Science Center at San Antonio
OTHER